Literature DB >> 26767712

Reply.

A Spinazzi1, G Pirovano1, N Shen1, M A Kirchin2.   

Abstract

Mesh：

Year:  2016        PMID： 26767712      PMCID： PMC7960143          DOI： 10.3174/ajnr.A4707

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


× No keyword cloud information.
  11 in total

1.  Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.

Authors:  Michael V Knopp; Val M Runge; Marco Essig; Marius Hartman; Olav Jansen; Miles A Kirchin; Albrecht Moeller; Astrid H Seeberg; Klaus-Peter Lodemann
Journal:  Radiology       Date:  2004-01       Impact factor: 11.105

2.  Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.

Authors:  H A Rowley; G Scialfa; P-y Gao; J A Maldjian; D Hassell; M J Kuhn; F J Wippold; M Gallucci; B C Bowen; I M Schmalfuss; J Ruscalleda; S Bastianello; C Colosimo
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-03       Impact factor: 3.825

3.  High agreement but low kappa: I. The problems of two paradoxes.

Authors:  A R Feinstein; D V Cicchetti
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

4.  Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents.

Authors:  Kenneth R Maravilla; Joseph A Maldjian; Ilona M Schmalfuss; Matthew J Kuhn; Brian C Bowen; Franz J Wippold; Val M Runge; Michael V Knopp; Stephane Kremer; Leo J Wolansky; Nicoletta Anzalone; Marco Essig; Lars Gustafsson
Journal:  Radiology       Date:  2006-06-26       Impact factor: 11.105

5.  Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Authors:  Z Seidl; J Vymazal; M Mechl; M Goyal; M Herman; C Colosimo; M Pasowicz; R Yeung; B Paraniak-Gieszczyk; B Yemen; N Anzalone; A Citterio; G Schneider; S Bastianello; J Ruscalleda
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

6.  Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention.

Authors:  Matthew J Kuhn; Piero Picozzi; Joseph A Maldjian; Ilona M Schmalfuss; Kenneth R Maravilla; Brian C Bowen; Franz J Wippold; Val M Runge; Michael V Knopp; Leo J Wolansky; Lars Gustafsson; Marco Essig; Nicoletta Anzalone
Journal:  J Neurosurg       Date:  2007-04       Impact factor: 5.115

7.  Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.

Authors:  Marco Essig; Armando Tartaro; Tomasso Tartaglione; Gianpaolo Pirovano; Miles A Kirchin; Alberto Spinazzi
Journal:  Acad Radiol       Date:  2006-06       Impact factor: 3.173

8.  A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours.

Authors:  C Colosimo; M V Knopp; X Barreau; E Gérardin; M A Kirchin; F Guézénoc; K P Lodemann
Journal:  Neuroradiology       Date:  2004-06-15       Impact factor: 2.804

9.  Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla.

Authors:  Zoran Rumboldt; Howard A Rowley; Fred Steinberg; Joseph A Maldjian; Jordi Ruscalleda; Lars Gustafsson; Stefano Bastianello
Journal:  J Magn Reson Imaging       Date:  2009-04       Impact factor: 4.813

10.  Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation.

Authors:  Lukas P Staub; Sarah J Lord; R John Simes; Suzanne Dyer; Nehmat Houssami; Robert Y M Chen; Les Irwig
Journal:  BMC Med Res Methodol       Date:  2012-02-14       Impact factor: 4.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.